

# ORUKA THERAPEUTICS, INC.

Reported by  
**AGARWAL ARJUN**

## FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 09/21/26 for the Period Ending 09/21/26

|             |                                                          |
|-------------|----------------------------------------------------------|
| Address     | 855 OAK GROVE AVE.<br>SUITE 100<br>MENLO PARK, CA, 94025 |
| Telephone   | 650-606-7910                                             |
| CIK         | 0000907654                                               |
| Symbol      | ORKA                                                     |
| SIC Code    | 2834 - Pharmaceutical Preparations                       |
| Industry    | Biotechnology & Medical Research                         |
| Sector      | Healthcare                                               |
| Fiscal Year | 12/31                                                    |

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

|                                                                                                                                                                                                                                                                                                                                           |                                                                                       |                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Name and Address of Reporting Person *<br><b>Agarwal Arjun</b><br><div>(Last) (First) (Middle)</div> <b>C/O ORUKA THERAPEUTICS, INC.</b><br><b>855 OAK GROVE AVE., SUITE 100</b><br><div>(Street)</div> <b>MENLO PARK CALIFORNIA 94025</b><br><div>(City) (State) (Zip/Postal Code)</div> <b>UNITED STATES</b><br><div>(Country)</div> | 2. Issuer Name and Ticker or Trading Symbol<br><b>Oruka Therapeutics, Inc. [ORKA]</b> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><div>Director 10% Owner</div> <div><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)</div> <b>Senior Vice President, Finance</b> |
| 3. Date of Earliest Transaction (MM/DD/YYYY)<br><b>9/21/2026</b>                                                                                                                                                                                                                                                                          |                                                                                       | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><div><input checked="" type="checkbox"/> Form filed by One Reporting Person</div> <div><input type="checkbox"/> Form filed by More than One Reporting Person</div>                 |
| 4. If Amendment, Date Original Filed (MM/DD/YYYY)                                                                                                                                                                                                                                                                                         |                                                                                       |                                                                                                                                                                                                                                                   |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security<br>(Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code<br>(Instr. 8) |   | 4. Securities Acquired (A) or Disposed of (D)<br>(Instr. 3, 4 and 5) |            |         | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|------------------------------------|----------------|-----------------------------------|------------------------------|---|----------------------------------------------------------------------|------------|---------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|                                    |                |                                   | Code                         | V | Amount                                                               | (A) or (D) | Price   |                                                                                                  |                                                          |                                                       |
| Common Stock                       | 9/21/2026      |                                   | S(1)                         |   | 533                                                                  | D          | \$95.75 | 14,219                                                                                           | D                                                        |                                                       |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivate Security<br>(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code<br>(Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)<br>(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date |                 | 7. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 3 and 4) |                            | 8. Price of Derivative Security<br>(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)<br>(Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------------------|--------------------------------------------------------|----------------|-----------------------------------|------------------------------|---|-------------------------------------------------------------------------------------------|-----------------------------------------|-----------------|--------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------|
|                                             |                                                        |                |                                   | Code                         | V |                                                                                           | Date Exercisable                        | Expiration Date | Title                                                                                | Amount or Number of Shares |                                               |                                                                                                       |                                                                                  |                                                        |

Explanation of Responses:

(1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

Reporting Owners

| Reporting Owner Name / Address                                                                                                       | Relationships |           |                                |       |
|--------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------|--------------------------------|-------|
|                                                                                                                                      | Director      | 10% Owner | Officer                        | Other |
| Agarwal Arjun<br>C/O ORUKA THERAPEUTICS, INC.<br>855 OAK GROVE AVE., SUITE 100<br>MENLO PARK<br>CALIFORNIA<br>94025<br>UNITED STATES |               |           | Senior Vice President, Finance |       |

Signatures

/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal

9/21/2026

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

\* Form 4: SEC 1474 (03-26).